Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections.

Park, Minah; Tan, Kelvin Bryan; Vasoo, Shawn; Dickens, Borame L; Lye, David; Cook, Alex R

Park, Minah; Tan, Kelvin Bryan; Vasoo, Shawn; Dickens, Borame L; Lye, David; Cook, Alex R.

Park M; Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
Tan KB; Ministry of Health, Singapore.
Vasoo S; National Centre for Infectious Diseases, Singapore.
Dickens BL; Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
Lye D; National Centre for Infectious Diseases, Singapore.
Cook AR; Saw Swee Hock School of Public Health, National University of Singapore, Singapore.

JAMA Netw Open ; 5(4): e225750, 2022 04 01.

Article in English | MEDLINE | ID: covidwho-1772626

Subject(s)

COVID-19; Antibodies, Monoclonal/therapeutic use; Antibodies, Viral; Humans; Outcome Assessment, Health Care; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: JAMA Netw Open Year: 2022 Document Type: Article Affiliation country: Jamanetworkopen.2022.5750

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google